Pontiro raises to scale NHS-grade anonymisation
UK healthcare data platform Pontiro has secured fresh funding to expand its privacy-first medical imaging anonymisation and AI evaluation capabilities across more NHS trusts.
Healthcare M&A News & Analysis
Healthcare M&A activity spans pharmaceuticals, biotechnology, medical devices, and healthcare services. The sector attracts both strategic consolidators seeking scale and private equity investors focused on platform building in specialized segments.
27 articles
EIB commits EUR 20m to SamanTree Medical
Belgian healthcare company SamanTree Medical has secured EUR 20 million in funding from the European Investment Bank, adding institutional firepower to its next phase of execution.
Evaro raises EUR 23.75m for UK digital health
UK healthcare platform Evaro has secured EUR 23.75 million in funding from a syndicate led by AlbionVC and Simplyhealth Ventures. The round signals continued investor appetite for care-access infrastructure despite limited disclosed terms.
Evaro raises EUR 23.75m to scale embedded digital healthcare
UK healthcare platform Evaro has secured EUR 23.75 million in Series A funding led by AlbionVC, with strategic participation from Simplyhealth Ventures and BBI. The round backs a model that lets consumer brands offer regulated digital healthcare services.
Verdane backs Clue in undisclosed funding round
German healthcare app Clue has received an undisclosed strategic investment from growth investor Verdane. Terms were not disclosed.
TargED raises EUR 21.5m to advance thrombosis therapies
Dutch biotech TargED Biopharmaceuticals has secured EUR 21.5 million in fresh funding from a syndicate of European life sciences investors to push its targeted approach to thrombotic diseases forward.
Keensight-backed Inke buys HPAPI site Pharmanoid
Keensight-backed inhalation API specialist Inke has acquired Pharmanoid, a manufacturing site focused on ophthalmic highly potent APIs, extending the platform beyond respiratory into adjacent therapeutic areas.
BioNTech closes CureVac deal to deepen mRNA stack
BioNTech has completed its acquisition of CureVac after 86.75% of shares were tendered, consolidating two German mRNA pioneers. The all-stock transaction sharpens BioNTech’s oncology focus and clears a long-running IP overhang.
FoRx raises EUR 50m to push PARG inhibitor into Phase I
Swiss precision oncology biotech FoRx Therapeutics has secured a EUR 50 million Series A led by repeat backers EQT Life Sciences, Novartis Venture Fund and Pfizer Ventures, with M Ventures participating. Proceeds fund Phase I development of lead asset FORX-428 with data expected by mid-2026.
MidEuropa takes majority stake in MBL Group
MidEuropa has acquired a majority stake in MBL Group, a European CDMO for assisted mobility, rehabilitation and aged care equipment. Terms were not disclosed; the Lauritsen family reinvested and management remains in place.
Liom raises EUR 13.9 million for glucose wearables
Swiss healthcare startup Liom has secured EUR 13.9 million in funding from Red Bull Ventures and individual investors. The round backs its wearable glucose monitoring technology as the category draws increasing capital and scrutiny.
Amplifold raises EUR 5m seed for DNA-origami diagnostics
German healthtech startup Amplifold has closed an oversubscribed EUR 5 million seed round led by Matterwave Ventures and XISTA Science Ventures to advance DNA origami-based signal amplification for rapid tests.
Melt&Marble raises EUR 7.3m to scale designer fats
Sweden’s Melt&Marble has closed a EUR 7.3 million Series A led by Industrifonden, with EIC Fund, Beiersdorf and Valio participating, to scale precision-fermented fats for personal care and food.
Bioxodes adds EUR 5.5m to fund BIOX-101 pivot
Belgian biotech Bioxodes raised EUR 5.5 million in a Series A extension with Newton Biocapital participating, taking its Series A to EUR 17.5 million as it prepares for a pivotal ICH trial.
EpilepsyGTx lands EUR 31.75m to advance epilepsy gene therapy
UK gene therapy start-up EpilepsyGTx has raised EUR 31.75 million in Series A funding from XGEN Venture, the British Business Bank and a global biopharma to take EPY201 into Phase 1/2a trials for focal refractory epilepsy.
Great Point buys into Lenis, backing CEE pharma distribution
Great Point Partners has acquired a majority stake in Slovenia-based Lenis Group, a regional commercialization and distribution partner for niche and specialty prescription medicines across Central and Eastern Europe.
Northern Gritstone backs IVFmicro’s embryo-culture tech
University of Leeds spinout IVFmicro has secured EUR 2.76 million to validate its microfluidic embryo-culture platform in fertility clinics, pushing toward human embryo trials.
Main backs Polypoint in healthcare workforce push
Main has invested an undisclosed amount in Polypoint, a healthcare workforce management specialist. The funding underscores steady investor appetite for operational software tied to staffing intensity in care delivery.
Punto Health lands EUR 2.3m seed for dementia care
London-based Punto Health has raised EUR 2.3 million in a seed round co-led by Shilling VC and Plus Partners to scale its AI-enabled dementia care platform and expand across the UK and Spain.
Aukera pulls Swiss bank into AI drug round
Aukera Therapeutics has raised CHF 4.5m (EUR 4.76m), bringing Zürcher Kantonalbank and seasoned biotech operator David Urech into an early-stage AI-enabled mTORC1 programme—an unusual show of risk appetite in today’s funding market.